Sign in Subscribe
Securities law

Sana Biotechnology Announces Planned Retirement of Bernard J. Cassidy and Appointment of Aaron M. Grossman

Strategic Insights

— 1 min read

Bernard J. Cassidy, Executive Vice President, General Counsel, and Corporate Secretary of Sana Biotechnology, Inc., has announced his planned retirement, effective October 20, 2025. Cassidy's departure is voluntary and for personal reasons, not a result of any disagreement with the company. His successor, Aaron M. Grossman, is expected to commence employment as the company's Executive Vice President, Chief Legal Officer, effective the same date.

Key Takeaways:

  • Bernard J. Cassidy is retiring as Executive Vice President, General Counsel, and Corporate Secretary of Sana Biotechnology, Inc. on October 20, 2025.
  • Cassidy's retirement is voluntary and for personal reasons, not a result of any disagreement with the company.
  • Aaron M. Grossman is expected to commence employment as the company's Executive Vice President, Chief Legal Officer, effective October 20, 2025.
  • Grossman's offer letter with the company includes transition-related services from Cassidy, contingent upon his retirement.
  • The company's board of directors has approved Grossman's appointment, which is expected to become effective as of immediately prior to the commencement of his employment with the company.
  • The company has disclosed forward-looking statements regarding Cassidy's retirement and Grossman's commencement of employment, which are subject to risks and uncertainties.

Statistics:

  • Sana Biotechnology, Inc. has 83-1381173 as its IRS Employer Identification Number.
  • The company has 188 East Blaine Street, Suite 400, Seattle, Washington 98102 as its principal executive offices.
  • The company's telephone number is (206) 701-7914.
  • Cassidy's retirement is expected to be effective October 20, 2025, contingent upon and effective as of immediately prior to the commencement of Grossman's employment.
  • Grossman is expected to commence employment as Executive Vice President, Chief Legal Officer, on October 20, 2025.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025
  • Sana Biotechnology, Inc., September 5, 2025 - Consent of Independent Registered Public Accounting Firm, prospectus filed with the U.S. Securities and Exchange Commission

Read more